Literature DB >> 19422457

Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice.

S A Maroney1, J P Ferrel, S Pan, T A White, R D Simari, J H McVey, A E Mast.   

Abstract

BACKGROUND: Mouse tissue factor pathway inhibitor (TFPI) is produced in three alternatively spliced isoforms that differ in domain structure and mechanism for cell surface binding. Tissue expression of TFPI isoforms in mice was characterized as an initial step for identification of their physiological functions. METHODS AND
RESULTS: Sequence homology demonstrates that TFPIalpha existed over 430 Ma while TFPIbeta and TFPIgamma evolved more recently. In situ hybridization studies of heart and lung did not reveal any cells exclusively expressing a single isoform. Although our previous studies have demonstrated that TFPIalpha mRNA is more prevalent than TFPIbeta or TFPIgamma mRNA in mouse tissues, western blot studies demonstrated that TFPIbeta is the primary protein isoform produced in adult tissues, while TFPIalpha is expressed during embryonic development and in placenta. Consistent with TFPIbeta as the primary isoform produced within adult vascular beds, the TFPI isoform in mouse plasma migrates like TFPIbeta in SDS-PAGE and mice have a much smaller heparin-releasable pool of plasma TFPIalpha than humans.
CONCLUSIONS: The data demonstrate that alternatively spliced isoforms of TFPI are temporally expressed in mouse tissues at the level of protein production. TFPIalpha and TFPIbeta are produced in embryonic tissues and in placenta while adult tissues produce almost exclusively TFPIbeta.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422457      PMCID: PMC2776060          DOI: 10.1111/j.1538-7836.2009.03454.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  42 in total

1.  Role for tissue factor pathway in murine model of vascular remodeling.

Authors:  R Singh; S Pan; C S Mueske; T Witt; L S Kleppe; T E Peterson; A Slobodova; J Y Chang; N M Caplice; R D Simari
Journal:  Circ Res       Date:  2001-07-06       Impact factor: 17.367

Review 2.  Function of alternative splicing.

Authors:  Stefan Stamm; Shani Ben-Ari; Ilona Rafalska; Yesheng Tang; Zhaiyi Zhang; Debra Toiber; T A Thanaraj; Hermona Soreq
Journal:  Gene       Date:  2004-12-10       Impact factor: 3.688

3.  A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice.

Authors:  Brian Pedersen; Todd Holscher; Yuichiro Sato; Rafal Pawlinski; Nigel Mackman
Journal:  Blood       Date:  2004-12-14       Impact factor: 22.113

Review 4.  Structure and biology of tissue factor pathway inhibitor.

Authors:  M S Bajaj; J J Birktoft; S A Steer; S P Bajaj
Journal:  Thromb Haemost       Date:  2001-10       Impact factor: 5.249

5.  Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor.

Authors:  J Marcus Lockett; Alan E Mast
Journal:  Biochemistry       Date:  2002-04-16       Impact factor: 3.162

6.  Active tissue factor pathway inhibitor is expressed on the surface of coated platelets.

Authors:  Susan A Maroney; Sandra L Haberichter; Paul Friese; Maureen L Collins; Josephine P Ferrel; George L Dale; Alan E Mast
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

7.  Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes.

Authors:  Paolo Golino; Amelia Ravera; Massimo Ragni; Plinio Cirillo; Orlando Piro; Massimo Chiariello
Journal:  Circulation       Date:  2003-12-01       Impact factor: 29.690

Review 8.  Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis.

Authors:  Rafal Pawlinski; Nigel Mackman
Journal:  Crit Care Med       Date:  2004-05       Impact factor: 7.598

9.  Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity.

Authors:  Todd A Hembrough; Jose F Ruiz; Bonnie M Swerdlow; Glenn M Swartz; Hans J Hammers; Li Zhang; Stacy M Plum; Mark S Williams; Dudley K Strickland; Victor S Pribluda
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

10.  Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor.

Authors:  T J Girard; L A Warren; W F Novotny; K M Likert; S G Brown; J P Miletich; G J Broze
Journal:  Nature       Date:  1989-04-06       Impact factor: 49.962

View more
  37 in total

1.  TFPIβ is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes.

Authors:  Thomas J Girard; Elodee Tuley; George J Broze
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

2.  Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases.

Authors:  Steffen Massberg; Lenka Grahl; Marie-Luise von Bruehl; Davit Manukyan; Susanne Pfeiler; Christian Goosmann; Volker Brinkmann; Michael Lorenz; Kiril Bidzhekov; Avinash B Khandagale; Ildiko Konrad; Elisabeth Kennerknecht; Katja Reges; Stefan Holdenrieder; Siegmund Braun; Christoph Reinhardt; Michael Spannagl; Klaus T Preissner; Bernd Engelmann
Journal:  Nat Med       Date:  2010-08-01       Impact factor: 53.440

3.  Re-evaluation of mouse tissue factor pathway inhibitor and comparison of mouse and human tissue factor pathway inhibitor physiology.

Authors:  T J Girard; K Grunz; N M Lasky; J P Malone; G J Broze
Journal:  J Thromb Haemost       Date:  2018-10-22       Impact factor: 5.824

4.  Mice, men, and differences therein.

Authors:  Alisa S Wolberg
Journal:  J Thromb Haemost       Date:  2019-09       Impact factor: 5.824

5.  Activated protein C up-regulates procoagulant tissue factor activity on endothelial cells by shedding the TFPI Kunitz 1 domain.

Authors:  Reto A Schuepbach; Kara Velez; Matthias Riewald
Journal:  Blood       Date:  2011-04-07       Impact factor: 22.113

Review 6.  Biology of tissue factor pathway inhibitor.

Authors:  Jeremy P Wood; Paul E R Ellery; Susan A Maroney; Alan E Mast
Journal:  Blood       Date:  2014-03-11       Impact factor: 22.113

Review 7.  Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.

Authors:  Pratima Chowdary
Journal:  Int J Hematol       Date:  2018-10-09       Impact factor: 2.490

8.  Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia.

Authors:  Susan A Maroney; Brian C Cooley; Josephine P Ferrel; Catherine E Bonesho; Lone V Nielsen; Peter B Johansen; Mette B Hermit; Lars C Petersen; Alan E Mast
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-21       Impact factor: 11.205

Review 9.  Platelet tissue factor pathway inhibitor modulates intravascular coagulation.

Authors:  Susan A Maroney; Alan E Mast
Journal:  Thromb Res       Date:  2012-03-17       Impact factor: 3.944

10.  Maintaining extraembryonic expression allows generation of mice with severe tissue factor pathway inhibitor deficiency.

Authors:  Michelle M Castillo; Qiuhui Yang; Min Zhan; Amy Y Pan; Michael W Lawlor; Alan E Mast; Rashmi Sood
Journal:  Blood Adv       Date:  2019-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.